Interferon-alpha is effective in patients with hairy cell leukemia relapsing after 2-chlorodeoxyadenosine (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Interferon-alpha is effective in patients with hairy cell leukemia relapsing after 2-chlorodeoxyadenosine (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A1033 1994. Unique Identifier : AIDSLINE ICDB/94601029
Seymour JF; Estey EH; Keating MJ; Kurzrock R; Department of Clinical Investigation, MD Anderson Cancer Center,; Houston, TX

Abstract: Interferon-alpha (IFN) produces responses in about 90% of patients (pts) with untreated hairy cell leukemia (HCL). 2-chlorodeoxyadenosine (2-CdA) induces a higher proportion of complete responses (CR) than IFN but also induces prolonged suppression of normal CD4+ and CD8+ lymphocyte counts. The optimal treatment of pts relapsing after 2-CdA is not known. Because T-cell suppression has not been observed after IFN therapy, we treated 3 pts with HCL relapsing 13 to 36 mo after 2-CdA with 3 x 10(6) U rIFN sc tiw. 2 pts had no prior IFN treatment, 1 had a prior CR of 14 mo after 6 mo of IFN. When starting IFN all 3 were neutropenic (1.1, 1.3, 1.5 x 10(3)/uL) and 2 were thrombocytopenic (66, 81 x 10(3)/uL). Duration of IFN therapy has been 22, 3+, and 6+ mo. All 3 pts have responded (1 CR, 1 PR, 1 MR) and the PR and MR pts continue on IFN. The pt who attained a CR has normal blood counts, but recurrent marrow infiltrate 3 mo after cessation of IFN. At the start of IFN, at a mean of 32 mo post 2-CdA, mean absolute CD4+ (normal 365-2400/uL) and CD8+ (normal 270-1600/uL) were 251/uL (range 199-302/uL) and 206/uL (34-431/uL), respectively. At a mean of 9 mo on IFN these remained stable, [mean CD4+ 233/uL (131-363/uL), CD8+ 196/uL (100-377/uL)]. IFN is an effective treatment option in pts with recurrent HCL after 2-CdA that does not worsen the persistent CD4+ lymphocytopenia.

Keywords: Cladribine/*THERAPEUTIC USE CD4-CD8 Ratio Human Interferon-alpha/*THERAPEUTIC USE Leukemia, Hairy Cell/*DRUG THERAPY/PATHOLOGY Recurrence ABSTRACT
941030
M94A0890

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .